

Global Pipeline



SHIONOGI

Global Pipeline – September 2015 (updated using Global August 2015 pipeline document)

Disease Area	Code No./ Product	Category (Administration)	Indication	Development Stage	Origin	Development
Infectious diseases	S-649266	Cephem antibiotic (Injection)	Infection	Global: Phase II	In-house	In-house
Cardiovascular / Diabetes	S-707106	Insulin sensitizer (Oral)	Type 2 Diabetes	USA: Phase IIa	In-house	In-house
	S-237648	Neuropeptide Y Y5 receptor antagonist (Oral)	Obesity	Japan: Phase II	In-house	In-house
Pain	S-297995 (Naldemedine)	Peripheral opioid receptor antagonist (Oral)	Alleviation of opioid-induced adverse effects	Global: Phase III Japan: Phase III	In-house	In-house
	S-117957	Analgesic agent for neuropathic pain (Oral)	Insomnia	USA: Phase 1	Shionogi/Purdue Pharma L.P. (USA)	Shionogi/Purdue Pharma L.P.
	S-120083	Analgesic agent for inflammatory pain (Oral)	Inflammatory pain	Japan: Phase I	Shionogi/Purdue Pharma L.P. (USA)	Shionogi/Purdue Pharma L.P.
	S-010887	Analgesic agent for neuropathic pain (Oral)	Neuropathic pain	Japan: Phase I	In-house	In-house
Women's Health	Ospemifene	Selective estrogen receptor modulator (Oral)	Post-menopausal vaginal atrophy	USA: Approval (Feb. 2013) Europe: Approval (Jan. 2015) Japan: Phase III	QuatRx Pharmaceuticals Company (USA)	Shionogi/QuatRx Pharmaceuticals Company
Other	S-555739	Prostaglandin D2 receptor antagonist (Oral)	Allergic rhinitis	USA: Phase IIa Europe: POM (Proof of Mechanism)	In-house	In-house
	S-888711 (Lusutrombopag)	Small molecule TPO receptor agonist (Oral)	Thrombocytopenia	USA: Phase IIa Japan: NDA submission (Dec. 2014) Global: Phase III	In-house	In-house
	S-646240	Peptide vaccine (Injection)	Age-related macular degeneration	Japan: Phase IIa	OncoTherapy Science, Inc. (Japan)	In-house
	S-588410	Cancer peptide vaccine (Injection)	Esophageal	Japan: Phase III	OncoTherapy Science, Inc. (Japan)	In-house
	S-488210	Cancer peptide vaccine (Injection)	Head and neck squamous cell carcinoma	Europe: Phase I/II	OncoTherapy Science, Inc. (Japan)	In-house
	S-222611	HER2/EGFR dual inhibitor (Oral)	Malignant tumor	Europe: Phase I/II	In-house	In-house

Out-Licensing Activity

Code No./ Product	Category (Administration)	Indication	Development Stage	Origin	Development
S/GSK1265744 LAP (Long acting parenteral formulation)	Integrase inhibitor (Injection)	HIV infection	USA: Phase II	Shionogi-ViiV HealthcareLLC	ViiV Healthcare Ltd.(UK)
S-0373	Non-peptide mimetic of TRH (Oral)	Spinocerebellar ataxia	Japan: Phase III	In-house	Kissei Pharmaceutical Co., Ltd, (Japan)
Janssen/ Shionogi BACE inhibitor	BACE inhibitor (Oral)	Alzheimer's disease	Europe: Phase IIa	In-house	Janssen Pharmaceuticals, Inc.(USA)